Cel Sci (CVM) Amortizatization of Intangibles (2017 - 2018)
Cel Sci (CVM) posted Amortizatization of Intangibles of $933340.0 for Q2 2018, up 126.89% sequentially from $411367.0 in Q1 2018, and up 4253.06% YoY from $21441.0 in Q2 2017.
Cel Sci (CVM) Amortizatization of Intangibles (2017 - 2018) Analysis & Trends
Cel Sci has reported Amortizatization of Intangibles for 2 years, with the latest figure at $933340.0 in Q2 2018.
- Quarterly Amortizatization of Intangibles rose 4253.06% year-over-year to $933340.0 in Q2 2018, while the trailing twelve-month figure through Mar 2019 was $933340.0 (down 51.91% YoY) and the FY2018 annual result came in at $2.0 million, up 113.19% from the prior year.
- Amortizatization of Intangibles climbed to $933340.0 in Q2 2018 per CVM's latest filing, from $411367.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $933340.0 in Q2 2018 and troughed at $21441.0 in Q2 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 933,340.00 |
| Jun 30, 2018 | 933,340.00 |
| Mar 31, 2018 | 411,367.00 |
| Mar 31, 2018 | 411,367.00 |
| Dec 31, 2017 | 611,717.00 |
| Dec 31, 2017 | 611,717.00 |
| Sep 30, 2017 | 896,251.00 |
| Sep 30, 2017 | 896,251.00 |
| Jun 30, 2017 | 21,441.00 |
| Jun 30, 2017 | 21,441.00 |